Use access key #2 to skip to page content.
$5.64 -0.07 (-1.23%)
9/5/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
*****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

1

Avatar msamet1 (97.88) Submitted: 3/30/07 10:17 AM : Underperform Start Price: $9.95 EXEL Score: 30.61

Midstage clinical targets have proven to be ineffective in widely treating cancers

Report this Post Replies: 0 | Reply

Featured Broker Partners